trial summary · NCT07592000
Breakthrough - T1DM and Chronic Kidney Disease
Multicenter, Phase 1/2 Pilot Study of Safety and Efficacy Assessment of Tegoprubart and Calcineurin Inhibitors- Free Immunosuppression Therapy for Pancreatic Islet Transplantation in Patients With T1DM and Chronic Kidney Disease
Trial record from the TrialBase DB dataset, status RECRUITING, condition Diabete Type 1, sponsored by University of Chicago. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years. Assess safety, tolerability, and efficacy of transplanted islet cells and immunomodulation with Tegoprubart in combination with anti-thymocyte globulin (ATG), etanercept and with everolimus in adults with brittle T1D and chronic kidney disease (stage 2-3a).
Source record: https://clinicaltrials.gov/study/NCT07592000
Facts
| registry id | NCT07592000 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Diabete Type 1 |
| sponsor | University of Chicago |
| sponsor class | OTHER |
| enrollment | 10 |
| start date | 2027-04-29 |
| primary completion | 2030-01-31 |
| completion | 2030-01-31 |
| results posted | not reported |
Conditions
- Diabete Type 1
- Chronic Kidney Disease
Interventions
- Tegoprubart
- Islet Cell Transplant
Countries
- United States
Intervention types: BIOLOGICAL, DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.